Eisai, Biogen continuing AD trial despite 12-month failure

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) said an IDMC determined that BAN2401 "did not meet the criteria for success" at 12 months on the primary endpoint in the Phase II Study 201 to treat prodromal or mild Alzheimer’s disease. The partners said the study will remain blinded and will continue until its final 18-month analysis, from which data are due in 2H18. BAN2401 is a humanized conformational specific IgG1 mAb targeting the toxic beta amyloid protofibrils.

Biogen slipped $10.95 to $322.52 on Thursday, shedding about $2.3 billion in market cap...